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Abstract
Type 2 diabetes is characterized by insulin resistance and progressive b-cell deterioration. As b-cell function
declines, most patients with type 2 diabetes treated with oral agents, in monotherapy or combination, will
require insulin therapy. Addition of basal insulin (glargine, detemir, or NPH/neutral protamine lispro insulin) to
previous treatment is accepted as the simplest way to start insulin therapy in those patients. But even when basal
insulin is adequately titrated, some patients will also need prandial insulin to achieve or maintain individual
glycemic targets over time. Starting with premixed insulin is an effective option, but it is frequently associated
with increased hypoglycemia risk, fixed meal schedules, and weight gain. As an alternative, a novel approached
known as ‘‘basal plus strategy’’ has been developed. This approach considers the addition of increasing injec-
tions of prandial insulin, beginning with the meal that has the major impact on postprandial glucose values.
Finally, if this is not enough intensification to basal–bolus will be necessary. In reducing hyperglycemia, this
modality still remains the most effective option, even in people with type 2 diabetes. This article will review the
currently evidence on the basal plus strategy and also its progression to basal–bolus therapy. In addition,
practical recommendations to start and adjust basal plus therapy will be provided.
Introduction
Type 2 diabetes mellitus (T2DM) is characterized by in-sulin resistance and progressive b-cell deterioration, ul-
timately leading to a condition of insulin deficiency.1 As b-cell
function declines, most patients with T2DM fail to maintain
adequate metabolic control with oral agents (OAs) and will
require insulin replacement over the time.2 Several clinical
studies have shown that tight control of blood glucose levels
in people with diabetes prevents the development and pro-
gression of the microvascular and macrovascular complica-
tions of diabetes.3–5 Therefore, when OAs as monotherapy or
in combination are not enough to achieve or maintain in-
vididual glycemic goals, addition of insulin is one of the most
preferred therapeutic options for people with T2DM.6 Insulin
is the most potent drug currently available to achieve tight
glycemic control. However, it is not used frequently timely or
aggressively enough to achieve the glycemic targets needed to
prevent chronic complications.7
When insulin should be added, addition of basal insulin (BI)
(glargine, detemir, or NPH/neutral protamine lispro [NPL]
insulin) to previousOAs is accepted as the simplestway to start
insulin therapy in people with T2DM.8–10 To be effective, BI
needs to be titrated based on fasting self-monitoring of blood
glucose (SMBG) (100–110mg/dL [5.5–6.1mmol/L]) when ad-
ministered once daily or before dinner/bedtime (‘‘Treat to
Target’’ concept).9,11 If a second injection of BI is necessary
(detemir or NPH/NPL insulin), morning insulin dose should
be also adjusted based on SMBG before dinner.12 This strategy
has been successful bringing a significant proportion of patients
(approximately 60–70%) to target,9,10 at least during the first 6–
12 months, or even up to 2–3 years.13 However, a remaining
important proportion of patients will need prandial insulin to
achieve or maintain glycemic objectives. Alternatively, recent
studies suggest that adding glucagon-like receptor-1 receptor
agonists or dipetidyl peptidase-4 inhibitors to BI may be also
effective and safe in this context,14,15 considering that some
patients may still retain enough pancreatic reserve.
Adding prandial insulin only (without BI) has been pro-
posed as another alternative to start insulin when failing OAs
in patients with T2DM. In terms of reduction of A1C, such a
strategy is as effective16 or even better17 than starting insulin
therapy with BI and achieves a superior postprandial con-
trol.16,18 However, this approach does not seem to result into
better cardiovascular outcomes in high cardiovascular risk
T2DM patients.18 Furthermore, the addition of prandial in-
sulin results in a greater incidence of hypoglycemia,16,17 even
when BI is successfully titrated to obtain comparable A1C
levels.16 For these reasons, when insulin is needed, BI is con-
sidered the preferred starting option.
Therefore, progressing in insulin therapy needs a combi-
nation of basal and prandial insulin. Between the different
1Diabetes Reference Unit, Endocrinology and Nutrition Department, Clinic University Hospital of Valencia, Valencia, Spain.
2Department of Medicine, University of Valencia, Valencia, Spain.
3Automatism and Industrial Informatic’s Institute, Polytechnic University of Valencia, Valencia, Spain.
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 13, Supplement 1, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/dia.2011.0001
S-75
therapeutic options, starting with premixed insulin twice or
three times daily is one of the most widely used options.19
Premixed insulin-based therapy, although effective in reduc-
ing hyperglycemia, is frequently associated with an increased
risk of hypoglycemia, a need of fixed meal schedules, and
weight gain.20,21 As an alternative to premixed insulin, basal–
bolus therapy (or multiple daily injections) still remains as the
most effective insulin strategy, even in peoplewith T2DM.22,23
Because this option is rarely accepted by patients, at least
initially, other options have been searched to facilitate a
stepwise intensification of insulin therapy in people with
T2DM when progressive deterioration of b-cell function is
inevitable. Recently, a new therapeutic option, known as
‘‘basal plus strategy,’’ has been evaluated in these patients
when BI in combination with OAs is not longer enough to
achieve glycemic goals.24
This article will review the currently evidence on the basal
plus strategy and also its progression to basal–bolus therapy
(Fig. 1). In addition, practical recommendations to start and
adjust basal plus therapy will be provided.
‘‘Basal Plus’’ Therapy
The concept of basal plus considers the addition of in-
creasing injections of prandial insulin, beginning with the
meal that has the major impact on postprandial glucose val-
ues, and maintaining previous treatment with BI and OAs.25
As explained below, this represents an effective strategy for
a ‘‘soft’’ transition to the more physiologic (and effective)
replacement of insulin by means of classical basal–bolus
therapy.24
When to move from basal to basal plus
Patients eligible to start basal plus therapy are those treated
with basal therapywith or without OAswho do not reachA1C
goals (<7.0% for most patients), even after adequate titration
of BI to target (100–110mg/dL [5.5–6.1mmol/L]).25 In addi-
tion, it has been suggested that also patients using high doses
of BI without success (>0.7U./kg) or who had limitations on
increasing BI doses because of high risk of nocturnal hypo-
glycemia are good candidates.26 Although evidence is scarce,
other patients may potentially profit of basal plus therapy,
as suggested by a recent experts’ document, summarized in
Table 1.26
Most patients will have a slightly elevated A1C (between
7.0% and 8.0%). Indeed, Monnier et al.27 have suggested that
excessive postprandial glucose excursions are the most im-
portant component of hyperglycemia for patients with less
elevated A1C levels (*7.3%). In addition, using continuous
glucose monitoring it has been demonstrated that high post-
prandial glucose levels are the first recognized glucose ab-
normality, especially after breakfast, even before fasting
glucose values deteriorates.28 Recently, it has been reported
that the relative contribution of postprandial hyperglycemia
increases to approximately 60% for an A1C below 8%, inde-
pendent of the A1C ranges, but only when BI is titrated ap-
propriately.29 In any case, it seems reasonable to suggest that
when patients are closed to the A1C target the addition of a
fitting dose of prandial insulin administered at the main meal
might be effective.
Review of the current evidence
Because the basal plus strategy is a relatively new concept
coming out in the last years, only a few trials have been
published until now. In the ‘‘Proof Of Concept’’ (POC) trial,
106 patients with T2DM treated with insulin glargine in
combination with OAs and A1C> 7.0% (60% women; age
[mean SD], 60 8 years; bodymass index, 33.3 4.8 kg/m2;
A1C, 7.9 0.6%; fasting plasma glucose, 111 22mg/dL)
were randomized to continue with the same treatment (con-
trol group) or to the addition of insulin glulisine before the
main meal (intervention group).30 After 3 months, patients
assigned to the glulisine group (0.14 0.07U/kg/day)
achieved a greater reduction of A1C (0.36 vs. 0.13% in the
control group, P¼ 0.029), without a significant increase of
hypoglycemic episodes. BI increased in the control group
from 0.59 0.26 to 0.65 0.32U/kg/day (no statistical value
reported), but not in the glulisine group (from 0.57 0.31 to
FIG. 1. Matching treatment to disease progression in type 2 diabetes mellitus using a stepwise approach. Adapted from
Raccah et al.24 Type 2 diabetes is a progressive disease marked by insulin resistance and increasing failure of the pancreatic
b-cell function. Therefore, as diabetes progresses, treatment will need to be intensified, including addition of insulin. Starting
basal insulin in addition to previous oral agents is the simplest way to initiate insulin therapy in people with type 2 diabetes.
When b-cell dysfunction progresses, prandial insulin is necessary and may be given using different strategies (see text). The
progression from basal therapy to basal plus, and then to basal–bolus therapy, is shown schematically.
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0.59 0.35U/kg/day). In addition, in the intervention group
a higher proportion of patients reached an A1C< 7.0% (22%
vs. 9% in the control group). This POC study confirmed that
the addition of only one injection of prandial insulin may
reduce further A1C by approximately 0.3–0.4% without in-
creasing the risk of hypoglycemia.
In the ‘‘Oral Plus Apidra and Lantus’’ (OPAL) trial, 393
patients with T2DM receiving treatment with insulin glargine
and OAs and insufficient glycemic control (mean basal A1C
was *7.4%) were randomized to the addition of insulin
glulisine before breakfast or before the main meal.31 The main
meal was defined as the meal associated with the highest
postprandial glycemic excursion based on several daily gly-
cemic profiles. The initial dose of insulin glulisine (*5U) was
individually increased in both groups, at the discretion of the
investigators, using a similar target of 2-h postprandial glu-
cose values for titration (135mg/dL [5.5mmol/L]). After
24 weeks, A1C was reduced similarly *0.4% in both groups
using similar doses of insulin glulisine (*11U), although a
greater proportion of patients reached the goal of A1C< 7.0%
in the main meal group (52% vs. 37% in the breakfast group).
No differences in the frequency of hypoglycemias were found
between the groups (*2.52 hypoglycemic events per patient
per year). Body weight increased similarly about *1 kg in
both groups.
In the ‘‘Optimisation of Insulin Treatment of Type 2 Dia-
betes Mellitus by Telecare Assistance for Self Monitoring of
Blood Glucose’’ (ELEONOR trial), 200 patients failing on one
or more OAs (54% men; age, 58.9 8.2 years; body mass in-
dex, 29.9 4.3 kg/m2; duration of diabetes, 10.9 6.9 years;
basal A1C, 8.9 0.9%) were randomized to insulin dose ad-
justment by either electronic transfer of capillary blood glu-
cose readings (Telecare program) or standard SMBG (control
group).32 After an initial phase of 8–16weeks, inwhich insulin
glargine was optimized to achieve fasting blood glucose
100mg/dL (5.5mmol/L), patients were randomized to
glulisine once daily, at the main meal, for an additional 24
weeks. Insulin glulisine adjustments in the follow-up were
based on postprandial glucose measurements (target, 100–
140mg/dL) using also Telecare or SMBG. Mean A1C de-
creased similarly from baseline to end point (8.8% to 7.1% for
Telecare; 8.9% to 7.0% for SMBG). The single injection of
glulisine was responsible for the last 0.7–0.8% decrement
(both P< 0.0001 vs. with glargine alone). The proportion with
A1C 7.0% at end point did not differ significantly between
the Telecare and SMBG groups (50.6% vs. 54.6%). There was
no difference in weight changes (Telecare vs. SMBG,
þ0.4 3.0 vs. þ0.1 5.0 kg), glargine final dose (29 16 vs.
28 17U/day), or glulisine final dose (8.3 7.1 vs.
8.1 8.1U/day). Severe hypoglycemia episodes were expe-
rienced by three subjects in the Telecare group and one patient
in the SMBG group. In this study, the efficacy of basal plus
strategy was unaffected by the insulin dose adjustment
method used.
The 1-2-3 trial was designed to evaluate the effectiveness of
the increasing addition of prandial insulin injections in pa-
tients with T2DM previously treated during a 14-week run-in
period with BI and OAs and having bad metabolic control.33
Thereafter, 343 patients (age, 53 years; body mass index,
37 kg/m2; A1C, 7.9%; fasting plasma glucose, 120mg/dL;
duration of diabetes, 10 years) were randomized to three
groups depending of the number of injections of insulin glu-
lisine administered before the main meal. After 24 weeks, A1C
values were reduced similarly in all groups (0.46% vs.
0.46% vs. 0.58% in the group with one, two, or three ad-
ditional injections of insulin glulisine, respectively). However,
the proportion of patients achieving anA1C 7.0%was higher
with increasing number of injections (30% vs. 33% vs. 45%
with one, two, or three injections of insulin glulisine, respec-
tively). In addition, the hypoglycemia rate increased with the
rising number of glulisine injections (0.10 vs. 0.30 vs. 0.26
events/patient/year with one, two, or three injections, re-
spectively), although only significantly higher when com-
paring the group with one versus two shots of insulin
glulisine (P¼ 0.043).
Recently, two additional trials have been reported evalu-
ating the efficacy and safety of the stepwise intensification of
prandial insulin. In one trial, 296 patients with T2DM and not
controlled with insulin detemir and OAs (mean values: age,
58.3 years; A1C, 8.8%; duration of diabetes, 12.3 years) were
randomized to stepwise addition of insulin aspart in the
largest perceivedmeal (n¼ 150) or in themeal with the largest
postprandial glucose increment (n¼ 146).34 After a run-in
period, in which basal doses were optimized, patients re-
ceived increasing doses of insulin aspart after 12-week peri-
ods if A1C was 7% according to the different protocols.
Sulfonylureas were discontinued before randomization. Both
strategies were equally effective in reducing A1C by *1.2%
Table 1. Selection of an Appropriate Candidate for Insulin Intensification with Basal Plus Therapy
Clinical situations Comments
Patients on basal insulin oral agents with
an A1C between 7.0% and 8.0%
Ideal candidates. A high percentage will achieve an A1C 7%.
Patients treated with 2 or 3 oral agents and
a high A1C> 8.5–9.0%
After optimized titration of basal insulin, addition of increasing
injections of prandial insulin will be necessary to reach
an A1C 7%.
Patients on basal insulin oral agents with an
A1C> 8% who are reluctant to start basal
bolus therapy
Basal plus should be considered as a transitional therapy to
progress steeply to basal–bolus therapy, which will be
necessary for most patients in this clinical situation.
Patients previously treated with premixed insulin
twice daily
For those with frequent hypoglycemia episodes and/or
irregular glycemic profiles, basal plus will offer an alternative.
Patients starting corticoid therapy for other
concomitant diseases
May be a valuable alternative to achieve stable daily
glycemic profiles, especially at lunch and dinner
Modified from Merchante et al.26
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(by*0.5% in period 1, by a further*0.5% in period 2, and by
*0.2% in period 3 in both groups). The overall rate of hy-
poglycemia was low, and weight gain was comparable, be-
tween 2.0 and 2.7 kg, at the end of the trial.
In the other trial, stepwise addition of prandial insulin
with or without discontinuation of sulfonylureas was com-
pared with the basal–bolus therapy in patients with type 2
diabetes.35 After a 6-month period in which insulin glargine
was optimized (36U/day; mean A1C, 8.3%), patients with
A1C> 7% and fasting plasma glucose <6.7mmol/L
(<120mg/dL) (n¼ 476) were then randomized to the three
different strategies. All patients received insulin glulisine as
prandial insulin, whichwas titrated according to postprandial
values. Increasing doses of insulin glulisine were added at 4-
month intervals upon the next meal with the highest post-
prandial glucose value. After 1 year, full basal–bolus therapy
was not superior to stepwise intensification of prandial in-
sulin, without or with sulfonylureas (change of A1C, 0.72%
vs. 0.47% vs. 0.40%, respectively; prespecified margin of
non-inferiority, 0.4%). Mean glulisine dose at end point was
29, 20, and 17U/day, respectively, with 33% and 40% of pa-
tients remaining on one glulisine injection in the group
without or with sulfonylureas. The incidence of symptomatic
hypoglycemia was highest with sulfonyluresa and lowest
without (between-group differences were not significant).
Weight gain was also significantly lower in the group with
stepwise addition of prandial insulin without sulfonylureas
compared with the basal–bolus group (þ1.30 vs. þ2.03 kg,
P< 0.05).
In summary, although the current evidence is still scarce
and the designs of the different trials were heterogeneous, the
addition of increasing number of prandial insulin injections
seems to be an effective and safe treatment modality. There-
fore, the basal plus strategy should be view as an alternative
for those patients treated with BI and OAs who are not able
to achieve or maintain their individual glycemic goals.36
Recently, this concept has been also incorporated in the
treatment algorithm supported by a group of experts from
the European Association for the Study of Diabetes and the
American Diabetes Association.11 However, the currently al-
gorithm is sparse regarding how to initiate, titrate, and in-
tensify prandial insulin doses.
Practical issues regarding basal plus strategy
How to initiate and titrate prandial insulin. In the basal
plus strategy, the initial dose of prandial insulin can be cal-
culated using different methods, although all of them offer
similar results (Table 2). To start, you can use a fixed dose or
find an individual dose depending on weight, previous BI
dose, or currently postprandial glucose values. Initiating with
a very small fixed dose is the simplest way to add prandial
insulin and avoid hypoglycemia, although this dose may be
very low depending on the patient. In any case, each health-
care provider should try one of the offered possibilities or
search for an alternative.
Finding the most appropriate dose of prandial insulin
safely requires using an adequate titration algorithm and
defining the most valuable glucose target. Insulin doses may
be adjusted based on either preprandial or postprandial glu-
cose values. Some guidelines recommend achieving a 2-h
postprandial glucose value lower than 140mg/dL
(7.8mmol/L),37,38 which in many cases means limiting the
glucose excursion to less than 40–50mg/dL (2.2–2.8mmol/
L).39 In the case of using rapid-acting insulin analogs (RAIAs),
adjustments based on postprandial glucose values seem to be
more worthwhile.
Increasing the dose of prandial insulin can be performed
with fixed dose increments (i.e., 1 or more units each time) or
depending of the previous prandial insulin dose or level of
postprandial glucose values (see Table 2). Titration should be
performed regularly based on SMBG. Patients should be in-
Table 2. Starting Prandial Insulin Dose and Adjustments Algorithm
Initiation dose of prandial insulin
Methods Initial dose
Fixed initial dose21 4U
Based on level of postprandial glucose values20 Glucose values (mmol/L)/2 (1mmol/L¼ 18mg/dL)
Based on patient’s weight26 0.05U/kg
Based on previous basal insulin dose27 10% of basal insulin dose
Adjustment algorithm
Methods Recommendations
Fixed-increments based on postprandial glucose values above target21 Postprandial glucose value >140mg/dL:
increase þ1U
Based on postprandial glucose values20 Between 136 and 153mg/dL: increase þ1U
Between 154 and 180mg/dL: increase þ2U
> 180mg/dL: increase þ3U
Based on previous prandial insulin dose if postprandial glucose
values are above target27
Dose 10U: increase þ1U
Dose 11–20U: increase þ2U
Dose >20U: increase þ3U
The frequency of dose adjustments should be individualized, but changes can be done every 3 days or weekly. Patients should be trained in
self-dose adjustments.
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structed to be able to implement titration algorithms at home.
Changing insulin doses when necessary every 3 days or
weekly seems to be reasonable.
Selection of the prandial insulin to be used will depend on
the patient’s characteristics, availability of insulin, and costs.
RAIAs (lispro, aspart, glulisine) have to be administered with
the meals and try to reproduce the rapid, potent, and short-
acting insulin-secretory response that takes place with en-
dogenous insulin after intake in individuals without diabetes.
Compared with regular insulin, RAIAs reduce postprandial
glycemic excursions more effectively, as well as the incidence
of late hypoglycemia (before the next intake).40 Moreover,
because of their rapid action, RAIAsmay be administered just
before the meal or even after, which is particularly appreci-
ated by some patients, in particular, by elderly persons with
unpredictable intake. In contrast, regular insulin requires
administration 30–45min before the meals, which in fact
rarely is accomplished by patients on a daily basis.
Finally, when basal plus therapy is implemented no chan-
ges in previous BI dose are necessary. However, it seems
logical to avoid nocturnal hypoglycemias, reducing the dose
of BI by*10% if the selected main meal to start with prandial
insulin is the dinner.26
Recommendations about the use of OAs in the basal plus
concept. In general, OAs used in combination with BI
should be maintained also in the basal plus strategy. Met-
formin should be continued and is beneficial in association
with insulin, irrespective of the insulin regimen. In relation to
glitazones (only currently pioglitazone is available in Europe),
although these agents may have potential benefits in some
patients, it seems prudent to avoid their combination with
insulin because of the potential for increased fluid retention
and weight gain. Other OAs such as sulfonylureas, glinides,
or dipeptidyl peptidase-4 inhibitors (sitagliptin) may be
maintained during basal plus. A recent study compared
continuation versus discontinuation of insulin secretagogues
(sulfonylureas and glinides) in addition to metformin when
initiating BI in patients with T2DM over 24 weeks.41 A1C re-
duction was similar in both groups (continuing vs. stopping
secretagogues, 1.59% vs. 1.30%, P¼ 0.382). However, in
patients continuing insulin secretagogues, although lower BI
doses were necessary, a higher hypoglycemia rate (40.0% vs.
24.5% with at least one symptomatic hypoglycemic event,
P< 0.001) and an increased weight gain (þ1.44 vs. þ0.43 kg,
P< 0.001) were found. Conversely, stopping these agents at
initiation of basal plus therapy may result in a significant in-
crease of insulin doses.26 In any case, when increasing pran-
dial insulin injections are needed, which may suggest a more
important deterioration of b-cell function, it will be advisable
to suspend treatment with sulfonylureas or glinides, and
probably also with dipeptidyl peptidase-4 inhibitors.42
Other aspects. In relation to how many and how often
patients should perform SMBG when transferring to basal
plus therapy, there are no well-established recommendations.
At the start, to identify the main meal, it will be necessary to
recollect at least two or three daily glycemic profiles, includ-
ing preprandial and 2-h postprandial glucose values after
breakfast, lunch, and dinner. These procedures should be re-
peated when increasing prandial insulin injections are needed
in order to identify the next main meal.
Regarding the titration process, prandial insulin doses
should be adjusted taking into consideration postprandial
(preferable) and preprandial (before the next meal) glucose
values. Therefore, in addition to monitor fasting blood glu-
cose to adjust prospectively BI doses, daily monitoring of
postprandial glucose values at least after the main meal is
important initially. If RAIAs are used, this practice is even
more important, and postprandial values remain the best in
the dosing process. When glucose values are stable, how
many times and how often SMBG should be performed by
patients should be established based on an individual basis.
Instructing patients on carbohydrate counting may be ad-
visable in some patients and can be very effective when used
in the context of a structured insulin dosing algorithm,22 but
in general this is not necessary and should not be im-
plemented in patients with T2DM transferred to the basal plus
strategy.
Transition to Basal–Bolus Approach
As commented on before, in clinical practice, the basal plus
strategy is acceptable for many patients. When b-cell dys-
function deteriorates further and more complicated insulin
regimens are needed, this therapeutic alternative may facili-
tate moving from the previous strategy of BI combined with
OAs, which is easier, to the basal–bolus therapy.43 Although
addition of a BI to OAs allows approximately 60–70% of
insulin-naive patients to achieve the goal of A1C< 7%,
9,10,12
data from the United Kingdom Prospective Diabetes Study
and Kumamoto studies clearly demonstrated that for most
patients attainment of glycemic goals requires early intensi-
fication of insulin therapy with the addition of prandial in-
sulin to basal.4,5,44,45 This concept has been recently confirmed
in the 3-year follow-up of the 4-T trial.46 However, the choice
between a basal–prandial and a premixed ‘‘biphasic’’ insulin
regimen, as well as the use of analogs instead of human in-
sulins, is a matter of debate.
Basal–bolus versus premixed insulins
When the intensification of hypoglycemic treatment is
needed, the use of prandial premixed insulin is an effective
option with a mean reduction in A1C of about 1.2–1.5%
23,47
and 45–50% of patients achieving an A1C< 7%.
48 In compar-
ison, the use of a basal–bolus strategy (four or five injections
per day) is associated with a slightly greater reduction in A1C
(about 1.5–1.8%) and a greater proportion of patients
achieving A1C< 7% (50–55%).
22,23,49,50 The high efficacy of
basal–bolus therapy in T2DM has been proven in the study
from Bergenstal et al.22 Here, a population of insulin-treated
(36% premixed, 37% glargine plus one or more shots of rapid-
acting insulin, 27% various other regimens) obese T2DM pa-
tients was switched to basal–bolus and randomized to two
different algorithms for prandial insulin titration. In-
dependent of the mealtime insulin dose adjustment strategy,
70–75% of subjects reached the goal of A1C< 7%, with a mean
reduction from baseline of about 1.5% in both groups. In the
very few direct comparisons between the premixed and
basal–bolus regimens,23,50,51 the latter resulted in a greater
proportion of patients in target (mean difference, 10–15%)
and better postprandial blood glucose.50,51 Also in the 4T
trial, although not specifically designed to compare a flexible
basal–boluswith premixed regimen over 3 years of follow-up,
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the superiority of basal–bolus was confirmed.46 In contrast, a
recently published substudy of the DURABLE trial52 suggests
no difference between the two insulin regimens. In this trial
two different premixed regimens (Lispro Mix 50/50 three
times a day or Lispro Mix 75/25 twice a day) achieved similar
results as basal–bolus therapy.52 However, glycemic control
was poor, with <20% of patients reaching the goal of
A1C< 7% regardless of treatment group. Therefore, non-
inferiority of premixed insulin was probably the result of
suboptimal treatment intensification.
Indeed, the basal–bolus approach is best suited to the ‘‘treat
to target strategy,’’ allowing for independent titration of both
basal and prandial insulin to address both pre- and post-
prandial hyperglycemia and more flexibility. In contrast,
premixed insulins (which contain fixed proportions of rapid-
and intermediate/long-acting insulin) are used preferentially
for targeting preprandial hyperglycemia.53 Of note is that
when an intensive approach is used, better glycemic control is
obtained with basal–bolus with a similar (or even lower) in-
cidence of hypoglycemia in comparison to premixed regi-
mens.23,50,51 For these reasons, premixed insulins should be
restricted only as nonintensive therapywith special caution in
patients with long-standing T2DM, who are likely to be more
insulin deficient and prone to hypoglycemia.54–56
Human insulins versus insulin analogs
Recently, it has been suggested that insulin analogs should
not be used in place of human insulin because they do not
improve glycemic control, providing only ‘‘minor’’ benefits in
terms of reduction of hypoglycemia.57–59 This recommenda-
tion is based on the results frommeta-analysis and systematic
reviews showing no benefit of insulin analogs over human
insulin, based on A1C reduction. However, measuring meta-
bolic control with only A1C may be misleading. In fact, RAIAs
have more favorable pharmacokinetics/pharmacodynamics
profile resulting in appreciable advantages compared with
regular human insulin, reflected by a higher reduction of
postprandial hyperglycemia and of postabsorptive hypogly-
cemia.40 In addition, long-acting insulin analogs show less
variability and reduction of nocturnal hypoglycemia com-
pared with NPH insulin.60 Consequently, improvement in
postprandial glycemic control along with the reduction of the
incidence of hypoglycemia is likely to result in lower glycemic
variability compared with human insulins. All these advan-
tages might have significant impact on diabetes-related
morbidity and mortality. Indeed, both acute and post-
prandial hyperglycemia61–65 and glucose variability65 might
theoretically contribute to the development/progression of
micro- and macroangiopathic complications and incidence of
cardiovascular events. In particular, a plethora of data from
basic science65 have shown that fluctuating glucose acti-
vates the pathways involved in the pathogenesis of diabetes
complications. On the other hand, retrospective analysis of
data from large clinical trials seems to rule out an indepen-
dent role of glycemic variability66 in clinical outcomes of
people with diabetes. Unfortunately, this apparent contrast
between basic science and clinical data will remain unsolved
until intervention trials aimed at reducing glucose vari-
ability demonstrate (or exclude) a reduction in the risk of di-
abetes complications. However, while waiting for an answer
that may never come, should we take care of glycemic vari-
ability? It is our opinion that yes, we should. Indeed, ad-
dressing variability probably allows for the reduction of
the incidence of hypoglycemia,67 the main complication of
diabetes treatment.
Results from the ACCORD and VADT studies have re-
cently emphasized the relationship between adverse out-
comes in T2DM and hypoglycemia, especially severe
hypoglycemia.68,69 Although this issue is neglected by some
authors,70 others underlined how relevant this issue is in
T2DM patients,71 increasing in frequency with progression of
the b-cell defect and impairment of hypoglycemia counter-
regulation.72 In this context, the irrational use of insulin may
lead to unnecessary increment in the rate of hypoglycemia
with potentially fatal adverse events, especially in the frail
elderly, who are rarely included in clinical trials.55 Therefore,
because of its better performance and safety profile compared
with human insulin, the combined use of BI and RAIAs may
contribute to improvement in the care of diabetes patients.
However, long-term trials are needed to find out if the above-
mentioned improvements in glucose control lead to improved
clinical outcomes.
Conclusions
Progressive deterioration of b-cell function in people with
T2DM is responsible for the initiation of insulin therapy when
OAs are not enough to achieve or maintain individual gly-
cemic goals. Addition of BI to previous OAs is the simplest
way to start insulin therapy in these patients. If this approach
is insufficient, adding prandial insulin is necessary over time.
Recently, the basal plus therapy (i.e., a stepwise introduction
of prandial insulin beginning with the main meal) has been
accepted as an effective and safe alternative to premixed in-
sulin. Additionally, this strategy will help patients if neces-
sary in the transition to basal–bolus therapy, which remain
the most effective and flexible insulin therapy even for people
with T2DM.
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